Market Overview

Gartner Acquires Capterra, no terms


Gartner, Inc. (NYSE: IT), the leading provider of research and analysis on
the global information technology industry, today announced the acquisition
of Capterra, a privately-held company based in Arlington, VA. Terms were not
Capterra helps organizations find the right business software to meet their
needs. The acquisition of Capterra is consistent with Gartner's growth
strategy to invest in developing world-class products and services that help
clients make the right technology-related decisions, every day.
Vista Point Advisors acted as the exclusive financial advisor to Capterra.
About Gartner
Gartner, Inc. (NYSE: IT) is the world's leading information technology
research and advisory company. The company delivers the technology-related
insight necessary for its clients to make the right decisions, every day.
From CIOs and senior IT leaders in corporations and government agencies, to
business leaders in high-tech and telecom enterprises and professional
services firms, to technology investors, Gartner is the valuable partner to
clients in approximately 10,000 distinct enterprises worldwide. Through the
resources of Gartner Research, Gartner Executive Programs, Gartner
Consulting and Gartner Events, Gartner works with every client to research,
analyze and interpret the business of IT within the context of their
individual role. Founded in 1979, Gartner is headquartered in Stamford,
Connecticut, USA, and has 7,100 associates, including more than 1,500
research analysts and consultants, and clients in 90 countries. For more
information, visit

Posted-In: M&A News


Related Articles (IT)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the World Muscle Society Congress

Why Virgin America Remains 'Underappreciated'